Trial results for tarlatamab in Chinese participants with advanced small cell lung cancer (SCLC) were posted on ClinicalTrials.gov on 2026-04-15. The Phase 2 study (NCT06502977) evaluated tarlatamab in participants with extensive stage SCLC after two or more prior lines of treatment. The study reported an objective response rate (ORR) of 38.7% for tarlatamab.
Background
The drug under investigation, tarlatamab, is also known by aliases such as imdelltra (amg757) and tarlatamab-dlle. This study focused on its potential in treating Extensive Stage Small Cell Lung Cancer, a condition for which new treatment options are continually sought, particularly after multiple prior lines of therapy.
Trial design
The study, identified as NCT06502977 and titled "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment," was a Phase 2 trial. It enrolled 32 participants diagnosed with Extensive Stage Small Cell Lung Cancer. The primary aim of the study was to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
Key results
For the outcome of "Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)":
- Participants in the Tarlatamab group achieved an objective response rate of 38.7 percentage of participants.
What this means
The reported objective response rate of 38.7% for tarlatamab in Chinese participants with advanced small cell lung cancer, following two or more prior lines of treatment, indicates a notable level of activity for the drug in this difficult-to-treat population. These results provide important data regarding the potential efficacy of tarlatamab as a therapeutic option for patients with extensive stage SCLC who have exhausted other treatment avenues.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT06502977, titled "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment," were posted on 2026-04-15 on clinicaltrials.gov.